Abstracts tagged "Cardiovascular disease"

Abstract Number: 631 • 2013 ACR/ARHP Annual Meeting
Type I IFN Regulation Of IL-10 Is Detrimental To Endothelial Cell Differentiation and May Enhance Cardiovascular Risk In Systemic Lupus Erythematosus
J. Michelle Kahlenberg¹, Alyssa Cates², Victoria Holden³, Carolyne K. Smith⁴ and Mariana J. Kaplan⁵, ¹Internal Medicine, Division of Rheumatology, University of Michigan, Ann Arbor, MI, ²Internal Medicine, Rheumatology, University of Michigan, Ann Arbor, MI, ³Pathology, University of Michigan, Ann Arbor, MI, ⁴Rheumatology and Graduate Program in Immunology, University of Michigan, Ann Arbor, MI, ⁵Systemic Autoimmunity Branch, National Institutes of Health/NIAMS, Bethesda, MD
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a heterogeneous disease resulting in organ damage and an elevated risk of cardiovascular disease (CVD). Previous reports have suggested…
Abstract Number: 388 • 2013 ACR/ARHP Annual Meeting
Vitamin D Levels and Inflammation In The Aortic Wall Of Patients With Inflammatory Rheumatic Disease and Coronary Artery Disease
Ingvild Oma¹, Jacqueline Kirsti Andersen², Torstein Lyberg³, Øyvind Molberg⁴, Jon Elling Whist¹, Ingjerd Lien Kvelstad¹, Terje Veel⁵, Morten Fagerland⁶, Sven M. Almdahl⁷, Knut Mikkelsen⁸ and Ivana Hollan⁹, ¹Innlandet Hospital Trust, Lillehammer, Norway, ²Gjøvik University College, Gjøvik, Norway, ³Oslo University Hospital, Oslo, Norway, ⁴Institute of Clinical Medicine, University of Oslo, Oslo, Norway, ⁵Feiringklinikken, Feiring, Norway, ⁶Department of Biostatistics, Oslo University Hospital, Oslo, Norway, ⁷Cardiothoracic surgery, University Hospital of North Norway, Tromsø, Norway, ⁸Lillehammer Hospital for Rheumatic Diseases, Lillehammer, Norway, ⁹Rheumatology, Lillehammer Hospital for Rheumatic Diseases, Lillehammer, Norway
Background/Purpose: Vitamin D is involved in immune reactions, and vitamin D deficiency is associated with autoimmune diseases and with cardiovascular diseases. In Feiring Heart Biopsy…
Abstract Number: 100 • 2013 ACR/ARHP Annual Meeting
Myocardial Infarction and Mortality after Joint Surgery in Patients with Rheumatoid Arthritis Compared with the General Population
Joanne Tropea¹, Mark Tacey², Megan Bohensky², Caroline Brand², Ian Wicks³ and Sharon Van Doornum², ¹Melbourne EpiCentre, Royal Melbourne Hospital, Melbourne, Australia, ²Melbourne EpiCentre, The University of Melbourne, Melbourne, Australia, ³Rheumatology Unit, Royal Melbourne Hospital, Melbourne, Australia
Background/Purpose: Rheumatoid arthritis (RA) is associated with an increased risk of myocardial infarction (MI) and post-MI fatality compared with the general population. In a previous…
Abstract Number: 2006 • 2013 ACR/ARHP Annual Meeting
Uric Acid Level Is Not An Independent Predictor Of Cardiovascular Diseases In Gout Patients With Treatment; Long-Term Follow-Up Data In Single Tertiary Center In South Korea
Seulkee Lee¹, Eun-Jung Park², Jinseok Kim³, Chan Hong Jeon⁴, Hyungjin Kim⁵, Jaejoon Lee¹, Eun-Mi Koh¹ and Hoon-Suk Cha¹, ¹Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, ²Internal Medicine, Department of Medicine, Jeju National University Hospital, Jeju University School of Medicine, Republic of Korea, Jeju, South Korea, ³Internal Medicine, Jeju National University Hospital, Jeju, South Korea, ⁴Internal Medicine, Soonchunhyang University College of Medicine, Bucheon, South Korea, ⁵Department of medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea
Background/Purpose: Hyperuricemia and gout are closely related conditions that are prevalent worldwide. A possible link between hyperuricemia and cardiovascular diseases (CVD) has been a debated…
Abstract Number: 1179 • 2013 ACR/ARHP Annual Meeting
Colchicine Use and The Risk Of Myocardial Infarction Among Gout Patients: Interim Results From a VA Retrospective Cohort Study
Daria B. Crittenden¹, Jessica N. Kimmel¹, Virginia C. Pike¹, Daniel Diaz¹, Avni Shah², Cilian J. White¹, Michael DeBerardine², Grace Kim², Binita Shah³, Christopher J. Swearingen⁴, Jeffrey D. Greenberg⁵, Steven P. Sedlis³, Craig T. Tenner⁶, Bruce N. Cronstein¹ and Michael H. Pillinger², ¹Internal Medicine, NYU School of Medicine, Division of Rheumatology, New York, NY, ²NYU School of Medicine, Division of Rheumatology, New York, NY, ³NYU School of Medicine, Division of Cardiology, New York, NY, ⁴Pediatric Biostatistics, University of Arkansas for Medical Sciences, Little Rock, AR, ⁵Division of Rheumatology, Department of Medicine, NYU Hospital for Joint Diseases, New York, NY, ⁶Internal Medicine, NYU School of Medicine, Department of Internal Medicine, New York, NY
Background/Purpose: Gout patients are at increased cardiovascular (CV) risk. Since atherosclerosis is an inflammatory process, anti-inflammatory strategies to reduce CV risk are currently being investigated.…
Abstract Number: 616 • 2013 ACR/ARHP Annual Meeting
Trends Of Mortality Associated To Systemic Lupus Erythematosus At The Nation Level: A Multiple Cause-Of-Death Analysis In France
Laurent Chiche Sr.¹, Guillemette Thomas², Albetine Aouba³, Julien Mancini⁴, Gabrielle Sarlon⁵, Noémie Jourde⁶, Eric Jougla³ and Jean-Robert Harle², ¹Internal Medicine, CHU Marseille, Marseille, France, ²Internal Medicine, APHM, Marseille, France, ³inserm CépiDc, paris, France, ⁴public health, APHM, Marseille, France, ⁵APHM, marseille, France, ⁶APHM, Marseille, France
Background/Purpose: The overall mortality rate of Systemic Lupus Erythematosus (SLE) has improved significantly over the past 50 years but is still high as compared with…
Abstract Number: 392 • 2013 ACR/ARHP Annual Meeting
Prevalence Of Cardiovascular Risk Factors and Cardiovascular Disease In Rheumatoid Arthritis Patients Across International Regions: A Comparison Of The Corrona International and Corrona United States Registries
Dimitrios A. Pappas¹, Kathy Lampl², Joel M. Kremer³, Sebastião C. Radominski⁴, Janos Gal⁵, Fredrik Nyberg⁶, Anand N. Malaviya⁷, Aimée Whitworth⁸, Oscar Luis Rillo⁹, Allan Gibofsky¹⁰, Tatiana Popkova¹¹, Meilien Ho¹², Ieda Laurindo¹³, George W. Reed⁸, Eduardo Mario Kerzberg¹⁴, Laura Horne¹⁵, Roman Záhora¹⁶, Katherine C. Saunders¹⁷, Bernado Pons-Estel¹⁸, Alina U. Onofrei¹⁹ and Jeffrey D. Greenberg²⁰, ¹Columbia University, New York, NY, ²AstraZeneca R&D Wilmington, Wilmington, DE, ³Center for Rheumatology, Albany Medical College, Albany, NY, ⁴Universidade Federal do Paraná, Curitiba, Brazil, ⁵Rheumatology, County Hospital, Kecskemet, Hungary, ⁶AstraZeneca R&D, Mölndal, Sweden, ⁷Rheumatology, Consultant Rheumatologist, ISIC Superspeciality Hospital, New Delhi-11007-, India, ⁸CORRONA, Inc., Southborough, MA, ⁹Hospital Tornú, Capital Federal, Argentina, ¹⁰Medicine and Public Health, Hospital for Special Surgery, New York, NY, ¹¹Research Institute of Rheumatology -Russian Academy of Medical Science, Moscow, Russia, ¹²AstraZeneca R&D Alderley Park, Macclesfield, United Kingdom, ¹³Rheumatology, Universidade de São Paulo, São Paulo, Brazil, ¹⁴Rheumatology, J. M. Ramos Mejía Hospital, School of Medicine, University of Buenos Aires, Buenos Aires, Argentina, ¹⁵AstraZeneca, Wilmington, DE, ¹⁶Revmatologická ambulance, Terezin, Czech Republic, ¹⁷Corrona, LLC., Southborough, MA, ¹⁸Hospital Provincial de Rosario, Rosario, Argentina, ¹⁹University of Massachusetts Medical School, Worcester, MA, ²⁰Rheumatology, NYU Hospital for Joint Diseases, New York, NY
Background/Purpose: Cardiovascular disease (CVD) is a major comorbidity in patients (pts) with rheumatoid arthritis (RA). We explored variations in the prevalence of cardiovascular (CV) risk…
Abstract Number: 20 • 2013 ACR/ARHP Annual Meeting
Complement Deposition On Platelets Is Associated To Venous Thrombosis In Systemic Lupus Erythematosus
Christian Lood¹, Helena Tydén¹, Birgitta Gullstrand², Gunnar Sturfelt³, Andreas Jönsen¹, Lennart Truedsson² and Anders A. Bengtsson¹, ¹Department of Clinical Sciences, Section of Rheumatology, Lund University, Lund, Sweden, ²Department of Laboratory Medicine, Section of Microbiology, Immunology and Glycobiology, Lund University, Lund, Sweden, ³Department of Clinical Sciences Lund, Section of Rheumatology, Lund University, Lund, Sweden
Background/Purpose: Anti-phospholipid (aPL) antibodies are associated with development of venous thrombosis and stroke in the autoimmune disease systemic lupus erythematosus (SLE). The underlying mechanism for…
Abstract Number: 1983 • 2013 ACR/ARHP Annual Meeting
Prevalence Of Birefringent Crystals In Three Inflammation-Prone Tissues
Jane Park¹, Divya Soman², Martine P. Roudier³ and Peter A. Simkin⁴, ¹Rheumatology, University of Washington, Seattle, WA, ²University of Washington, Seattle, WA, ³Pathology, University of Washington, Seattle, WA, ⁴Div of Rheumatology, University of Washington, Seattle, WA
Background/Purpose: When serum is hyperuricemic, so too are all interstitial fluids other than CSF and sweat. Anecdotally, urate crystals deposit as grossly visible tophi in…
Abstract Number: 1190 • 2013 ACR/ARHP Annual Meeting
The Synergistic Effects Of Metabolic Syndrome Indicators and Hyperuricemia In Contributing To Cardiac Event Risk: A Cross-Sectional Examination Of The Nhanes III Data
Daniel A. Albert^1,2 and Sayyad Kyazimzade³, ¹Medicine/Rheumatology, Dartmouth-Hitchcock Medical Center, Lebanon, NH, ²Rheumatology, The Dartmouth Institute for Health Policy and Clinical Practice, Lebanon, NH, ³The Dartmouth Institute for Health Policy & Clinical Practice, Lebanon, NH, Lebanon, NH
Background/Purpose: The focus of this project is to assess the contribution of hyperuricemia and gout to the risk for cardiovascular events. In a preliminary analysis…
Abstract Number: 584 • 2013 ACR/ARHP Annual Meeting
The Effect Of Ramipril On Endothelial Function and Endothelial Progenitor Cells In Patients With Systemic Lupus Erythematosus
Emilia I. Sato¹, Luiz Samuel G. Machado² and Ana Cecilia Machado³, ¹Rheumatology Div/Dept of Med, Escola Paulista de Medicina - Universidade Federal de São Paulo, Sao Paulo, Brazil, ²Rheumatology, Universidade Federal de São Paulo, São Paulo, Brazil, ³Medicina, Universidade Federal de São Paulo, São Paulo, Brazil
Background/Purpose: Cardiovascular diseases (CVD) are one of major causes of morbidity and mortality in SLE patients. Traditional cardiovascular risk factors and disease intrinsic factors contribute…
Abstract Number: 364 • 2013 ACR/ARHP Annual Meeting
Hyperuricemia As a Risk Factor for Cardiovascular Disease in Patients With Rheumatoid Arthritis
Daniel Kuo¹, Cynthia S. Crowson², Sherine E. Gabriel³ and Eric L. Matteson⁴, ¹Mayo Medical School, Mayo Clinic, Rochester, MN, ²Department of Health Sciences Research, Mayo Clinic, Rochester, MN, ³Health Sciences Research & Div of Rheumatology, Mayo Clinic, Rochester, MN, ⁴Rheumatology, Mayo Clinic, Rochester, MN
Background/Purpose: Patients with rheumatoid arthritis (RA) are at increased risk of developing cardiovascular disease (CVD). There is growing evidence that serum uric acid plays an important…
Abstract Number: 2898 • 2013 ACR/ARHP Annual Meeting
Atherosclerosis In Systemic Lupus Erythematosus (SLE) and Controls, -An Analysis Of SLE Subgroups
Johanna Gustafsson¹, Kerstin Jensen-Urstad², Marie Herlitz-Lindberg², Sonia Möller¹, Susanne Pettersson¹, Iva Gunnarsson¹, Anders Larsson³ and Elisabet Svenungsson⁴, ¹Department of Medicine, Rheumatology Unit, Karolinska Institutet, Stockholm, Sweden, ²Department of Clinical Physiology, Södersjukhuset, Karolinska Institutet, Stockholm, Sweden, ³Department of Clinical Chemistry and Pharmacology, Akademiska Hospital, Uppsala, Sweden, ⁴Department of Medicine, Unit of Rheumatology, Karolinska Institutet, Stockholm, Sweden
Background/Purpose: Atherosclerosis is often assumed to be the main underlying cause of premature vascular events (VE) among patients with systemic lupus erythematosus (SLE) and accelerated…
Abstract Number: 1986 • 2013 ACR/ARHP Annual Meeting
Colchicine Use and The Risk Of Myocardial Infarction Among Gout Patients: Results From a Community-Based, Informatics-Driven Retrospective Cohort Study
Daria B. Crittenden¹, Binita Shah², Steven P. Sedlis², Christopher J. Swearingen³, Eric S. Wagner⁴, Yvette M. Henry⁴, Peter B. Berger⁴, Bruce N. Cronstein¹ and Michael H. Pillinger⁵, ¹Internal Medicine, NYU School of Medicine, Division of Rheumatology, New York, NY, ²NYU School of Medicine, Division of Cardiology, New York, NY, ³Pediatric Biostatistics, University of Arkansas for Medical Sciences, Little Rock, AR, ⁴Geisinger Health System, Cardiovascular Center for Clinical Research, Danville, PA, ⁵NYU School of Medicine, Division of Rheumatology, New York, NY
Background/Purpose: Gout patients have an increased risk of myocardial infarction (MI). Since atherosclerosis and plaque rupture are inflammatory processes, anti-inflammatory gout medications might also reduce…
Abstract Number: 1036 • 2013 ACR/ARHP Annual Meeting
The Independent Impact Of Depression On Incident Myocardial Infarction In Psoriatic Disease: A Population-Based Cohort Study
Lindsay C Burns^1,2, Jan P. Dutz¹ and Hyon Choi^3,4,5, ¹Department of Dermatology and Skin Science, University of British Columbia, Vancouver, BC, Canada, ²Research, Arthritis Research Centre of Canada, Richmond, BC, Canada, ³Arthritis Research Centre of Canada, Richmond, BC, Canada, ⁴Section of Rheumatology and the Clinical Epidemiology Unit, Boston University School of Medicine, Boston, MA, ⁵Division of Rheumatology, Allergy, and Immunology Massachusetts General Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Psoriasis (PsC) and psoriatic arthritis (PsA) represent common, lifelong inflammatory diseases of the skin and joints (respectively) that are associated with substantial cardiovascular and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].